Cindy Xinxin Du1, Julia Shi2,3, Jeanette M Tetrault2,3, Lynn M Madden2,3, Declan T Barry3,4. 1. Yale University School of Medicine, New Haven, CT, United States. 2. Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, United States. 3. The APT Foundation Inc., New Haven, CT, United States. 4. Department of Psychiatry, Yale University School of Medicine, New Haven, CT, United States.
Abstract
BACKGROUND: Office-based opioid treatment (OBOT) is an evidence-based treatment model for opioid use disorder (OUD) offered by both addiction and general primary care providers (PCPs). Calls exist for more PCPs to offer OBOT. Few studies have been conducted on the primary care characteristics of OBOT patients. OBJECTIVE: To characterize medical conditions, medications, and treatment outcomes among patients receiving OBOT with buprenorphine for OUD, and to describe differences among patients by age and by time in care. METHODS: This study is a retrospective review of medical records on or before 4/29/2019 at an outpatient primary care clinic within a nonprofit addiction treatment setting. Inclusion criterion was all clinic patients actively enrolled in the OBOT program. Patients not prescribed buprenorphine or with no OBOT visits were excluded. RESULTS: Of 355 patients, 42.0% had another PCP. Common comorbid conditions included chronic pain and psychiatric diagnosis. Few patients had chronic viral hepatitis or HIV. Patients reported a median of 4 medications. Common medications were cardiovascular, antidepressant, and nonopioid pain agents. Older patients had a higher median number of medications. There was no significant difference in positive opioid urine toxicology (UT) based on age, chronic pain status, or psychoactive medications. Patients retained >1 year were less likely to have positive opioid UT. CONCLUSION: Clinical needs of many patients receiving OBOT are similar to those of the general population, supporting calls for PCPs to provide OBOT. Published by Oxford University Press 2021.
BACKGROUND: Office-based opioid treatment (OBOT) is an evidence-based treatment model for opioid use disorder (OUD) offered by both addiction and general primary care providers (PCPs). Calls exist for more PCPs to offer OBOT. Few studies have been conducted on the primary care characteristics of OBOT patients. OBJECTIVE: To characterize medical conditions, medications, and treatment outcomes among patients receiving OBOT with buprenorphine for OUD, and to describe differences among patients by age and by time in care. METHODS: This study is a retrospective review of medical records on or before 4/29/2019 at an outpatient primary care clinic within a nonprofit addiction treatment setting. Inclusion criterion was all clinic patients actively enrolled in the OBOT program. Patients not prescribed buprenorphine or with no OBOT visits were excluded. RESULTS: Of 355 patients, 42.0% had another PCP. Common comorbid conditions included chronic pain and psychiatric diagnosis. Few patients had chronic viral hepatitis or HIV. Patients reported a median of 4 medications. Common medications were cardiovascular, antidepressant, and nonopioid pain agents. Older patients had a higher median number of medications. There was no significant difference in positive opioid urine toxicology (UT) based on age, chronic pain status, or psychoactive medications. Patients retained >1 year were less likely to have positive opioid UT. CONCLUSION: Clinical needs of many patients receiving OBOT are similar to those of the general population, supporting calls for PCPs to provide OBOT. Published by Oxford University Press 2021.
Entities:
Keywords:
buprenorphine; medications for opioid use disorder; opiate substitution treatment; opioid-related disorders; polypharmacy; primary health care
Authors: Jonathan D Savant; Declan T Barry; Christopher J Cutter; Michelle T Joy; An Dinh; Richard S Schottenfeld; David A Fiellin Journal: Drug Alcohol Depend Date: 2012-07-06 Impact factor: 4.492
Authors: Zoe M Weinstein; Hyunjoong W Kim; Debbie M Cheng; Emily Quinn; David Hui; Colleen T Labelle; Mari-Lynn Drainoni; Sara S Bachman; Jeffrey H Samet Journal: J Subst Abuse Treat Date: 2016-12-30
Authors: Emma E McGinty; Elizabeth M Stone; Alene Kennedy-Hendricks; Marcus A Bachhuber; Colleen L Barry Journal: Ann Intern Med Date: 2020-04-21 Impact factor: 25.391
Authors: Declan T Barry; Kevin S Irwin; Emlyn S Jones; William C Becker; Jeanette M Tetrault; Lynn E Sullivan; Helena Hansen; Patrick G O'Connor; Richard S Schottenfeld; David A Fiellin Journal: J Gen Intern Med Date: 2008-12-17 Impact factor: 5.128
Authors: Anne Berit Bech; Thomas Clausen; Helge Waal; Jūratė Šaltytė Benth; Ivar Skeie Journal: BMC Health Serv Res Date: 2019-07-02 Impact factor: 2.655